Zobrazeno 1 - 10
of 25
pro vyhledávání: '"María José Juan-Fita"'
Autor:
Rebeca Lozano, Elena Castro, Fernando Lopez-Campos, Heather Thorne, Miguel Ramirez-Backhaus, Isabel M. Aragon, Ylenia Cendón-Florez, Ana Gutierrez-Pecharroman, Daniela C. Salles, Nuria Romero-Laorden, David Lorente, Pilar González-Peramato, Ana Calatrava, Concepción Alonso, Urbano Anido, Sara Arévalo-Lobera, Judith Balmaña, Isabel Chirivella, María José Juan-Fita, Gemma Llort, Teresa Ramón y Cajal, Elena Almagro, Daniel Alameda, Pedro P. López-Casas, Bernardo Herrera, Joaquin Mateo, Colin C. Pritchard, Emmanuel S. Antonarakis, Tamara L. Lotan, José Rubio-Briones, Shahneen Sandhu, David Olmos
Publikováno v:
European Journal of Cancer. 185:105-118
Autor:
Gabriele Zoppoli, William Audeh, Theodora Goulioti, David Cameron, Iain R. Macpherson, Marco Colleoni, Antonino Musolino, Luis Manso, Audrey Mailliez, Evangelia Razis, Andrew Tutt, Virginie Adam, Peter Vuylsteke, John K. Erban, Michail Ignatiadis, Kai Yu Jen, István Láng, Bella Kaufman, Aafke H. Honkoop, Konstantinos Tryfonidis, Saskia Litière, Oskar T. Johannsson, Judith Balmaña, Olivier Tredan, Susan Ellard, Nicholas C. Turner, María José Juan-Fita, Lori J. Goldstein, C. Poncet
Publikováno v:
Clinical cancer research, 27 (20
Clin Cancer Res
2021, ' Niraparib for advanced breast cancer with germline BRCA1 and BRCA2 mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO study ', Clinical Cancer Research . https://doi.org/10.1158/1078-0432.CCR-21-0310
Clin Cancer Res
2021, ' Niraparib for advanced breast cancer with germline BRCA1 and BRCA2 mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO study ', Clinical Cancer Research . https://doi.org/10.1158/1078-0432.CCR-21-0310
Purpose: To investigate the activity of niraparib in patients with germline-mutated BRCA1/2 (gBRCAm) advanced breast cancer. Patients and Methods: BRAVO was a randomized, open-label phase III trial. Eligible patients had gBRCAm and HER2-negative adva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96a1bfde4ac52e52c38e495f34c523cc
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/333689
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/333689
Autor:
Antonio Salvador, Adoración Egido, Mateo Quispe, Javier Lavernia, Miguel Angel Climent, Isidro Machado, Héctor Augusto Aguilar, José Rubio-Briones, Maria Asunción Algarra, Pablo Álvarez, María José Juan Fita, Sergio Sandiego
Publikováno v:
ecancermedicalscience
Secondary amyloidosis is a rare complex complication related to chronic inflammatory disease. This complication is sparsely associated to malignant neoplasms. Renal cell carcinoma (RCC) is the most common solid organ malignancy related with this para
Autor:
Lucia Inglada Pérez, Francisco Zambrana, María José Juan Fita, Cristina López, S. Ros, Alicia Barroso, Ana María Autran, Isabel Lorenzo‐Lorenzo, Guillermo Pita, Ignacio Duran, Xavier Garcia del Muro, Fatima Al-Shahrour, Javier Benitez, Vanesa Quiroga, Enrique González Billalabeitia, Javier Sastre, Miguel Urioste, Héctor Tejero, Juan Moreno, Antonio Fernández Aramburo, Claudia Valverde, Juan Carlos Triviño, Patricia Iranzo, Beatriz Paumard-Hernández, Pablo Maroto, Oriol Calvete
Publikováno v:
International Journal of Cancer
Testicular germ cell tumors (TGCTs) are a clinically and pathologically heterogeneous disease, and little is known of its genetic basis. Only low susceptibility risk loci have been identified for both sporadic and familial cases. Therefore, we tried
Autor:
Ovidio Fernandez Calvo, Maria Ochoa de Olza, Urbano Anido, María José Juan Fita, Laura Muinelo Romay, Begoña Mellado, Miguel Angel Climent, Cristina Caballero, Montserrat Domenech, Daniel Castellano, Jose Angel Arranz Arija, Begoña Perez-Valderrama, Susana Hernando Polo, Eva Fernandez Parra
Publikováno v:
European Journal of Cancer. 87:30-37
Aim Cabazitaxel (CBZ), a novel tubulin-binding taxane, improves overall survival in metastatic castration-resistant prostate cancer (mCRPC) that progresses during or after docetaxel treatment. We have designed a phase II study to evaluate the efficac
Autor:
Ana Beatriz Sánchez Heras, Isabel Chirivella González, Cecilia Egoavil Rojas, Marta Llop García, Zaida García-Casado, Inmaculada de Juan Jiménez, Gema Pérez Simó, Sarai Palanca Suela, María José Juan Fita, José Antonio López Guerrero, Ángel Segura Huerta, Rosa Murria Estal, Ana Santaballa Bertran, Eva Barragán González, Cristina Alenda Gonzalez, Pascual Bolufer Gilabert
Publikováno v:
Familial Cancer. 15:193-200
The study aims to identify the relevance of immunohistochemistry (IHC), copy number aberrations (CNA) and epigenetic disorders in BRCAness breast cancers (BCs). We studied 95 paraffin included BCs, of which 41 carried BRCA1/BRCA2 germline mutations a
Autor:
Pablo Maroto, Javier Cassinello, Martin Lázaro Quintela, Jose Angel Arranz Arija, Emilio Esteban, Ignacio Duran, Alfredo Sanchez-Hernandez, Daniel Castellano, María José Juan Fita, Miguel Angel Climent Duran, Javier Puente, Teresa Alonso Gordoa, María José Méndez Vidal, Albert Font, Begoña Mellado, Aranzazu Gonzalez del Alba, Carmen Santander, M Isabel Sáez, Begoña P. Valderrama
Publikováno v:
Journal of Clinical Oncology. 38:95-95
95 Background: Abiraterone acetate (AA) improves OS and rPFS in first line mCRPC patients (pts). After AA progression D is commonly used as standard second line therapy. However, the value of maintaining AA in combination with D despite progression h
Autor:
Estela Carrasco, Francesc Balaguer, Alexandre Teule, Maite Herraiz, C. Alonso-Cerezo, Judith Balmaña, Encarna Adrover, Sonia Servitja, Ariadna Sánchez, R. Serrano, Ana M. Casas, S. Khorrami, S. Gonzalez-Santiago, Antonio Antón, M.J. Oruezábal-Moreno, María José Juan-Fita, Alberto Herreros-de-Tejada, Juana María Cano, A. Angulo, Gemma Llort, Begoña Graña, M.H. López-Ceballos, Joan Brunet, Carmen Guillén-Ponce, J.E. Alés-Martínez, Joaquín Cubiella, Neus Gadea, Teresa Ocaña, Rafael Morales, I. Esteban, I. Garau, Salvador Martinez, M. Vilaró, E. Alba, Lucía Cid, Ana Beatriz Sánchez-Heras, R. Jover
Publikováno v:
PSYCHO-ONCOLOGY
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
r-FISABIO. Repositorio Institucional de Producción Científica
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
r-FISABIO. Repositorio Institucional de Producción Científica
ObjectivePatients' psychological reactions to multigene cancer panel testing might differ compared with the single-gene testing reactions because of the complexity and uncertainty associated with the different possible results. Understanding patients
Autor:
Begoña Mellado, Eva Fernandez Parra, Jose Angel Arranz, B. Pérez-Valderrama, María José Juan Fita, Susana Hernando Polo, Cristina Caballero Diaz, Urbano Anido Herranz, Montserrat Domenech, Daniel Castellano, Ovidio Fernandez Calvo, Maria Ochoa de Olza, Miguel Angel Climent Duran
Publikováno v:
Journal of Clinical Oncology. 37:176-176
176 Background: Cabazitaxel (CBZ) improves overall survival in mCRPC that progresses during or after docetaxel treatment. CABASEM is a phase II study to evaluate the efficacy and safety of a weekly schedule of CBZ for 'unfit' (ECOG2, previous neutrop
Autor:
Alejandro gonzalez Forastero, Ignacio Duran, Cristina Caballero Diaz, Isabel Chirivella, A. Montesa, David Olmos, Lucia Heras, M Isabel Sáez, María José Juan Fita, Sergio Vazquez-Estevez, Begoña Mellado, Josep M. Piulats, Miguel Angel Climent Duran
Publikováno v:
Journal of Clinical Oncology. 37:198-198
198 Background: Different treatments efficacy for mCRPC when progression after docetaxel x 6 cycles + ADT (as CHAARTED scheme) are unknown as all pivotal trials where performed in patients who progressed to mCPRC after ADT. Methods: A retrospective a